Additional early-stage research and drug discovery news in brief, from: Cereno Scientific, Gri Bio, Palisade Bio, Panavance Therapeutics, Zyversa Therapeutics.
Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Gruenenthal GmbH has patented new cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives acting as nociceptin receptor (OPRL1; KOR3; ORL1) agonists and thus reported to be useful for the treatment of pain.
Sanofi SA has synthesized pyridoimidazolone compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.
At the American Heart Association’s Scientific Sessions, E-Therapeutics plc presented preclinical data for ETX-258, a Galomic siRNA being developed for the treatment of heart failure.
The Wiskott-Aldrich syndrome protein (WASp) is expressed exclusively in hematopoietic cells and presents either an autoinhibited or activated conformation. EG-011 is a first-in-class activator of the autoinhibited form of WASp designed for the treatment of hematological cancers.
Researchers from Ohio State University hypothesized that 12,13-diHOME may act by inhibiting the proarrhythmic molecule Ca2+/calmodulin-dependent kinase II (CaMKII).
RSS
